Horizon 2020 Medicafé Få EU-støtte til forskningsog innovationsprojekter
Medico Innovation Innovation Network for the Danish MedTech Industry o o o Researchers Business people Health care employees Partners: Funded by: November 2013
creodk Joint EU research office in Brussels help researchers with the EU framework programmes for research and innovation Partners: November 2013
Horizon 2020 The EU Framework Programme for Research and Innovation 2014 2020 70 billion ~ 525 mia. DKK Create new growth and jobs in Europe Three areas: o o o Tackling Societal Challenges ~ 204 mia. DKK Competitive Industries ~ 117 mia. DKK Excellent Science ~ 168 mia. DKK November 2013
SME s in Horizon 2020 a minimum of 20 %, or about 8.65 billion, of the total combined budgets new dedicated SME instrument funding for early-stage, high-risk research and innovation by SMEs as well as stimulating breakthrough innovation targets highly innovative SMEs showing a strong ambition to develop, grow and internationalise, regardless of whether they are high-tech and researchdriven or nonresearch conducting, social or service companies November 2013
Program 15:10-15:20 Horizon 2020 hvad er det og hvad er nyt ved Jonas Bak, EU-konsulent, creodk 15:20-15:30 Overblik over medicoopslag i Horizon 2020 i 2014+2015 ved Lars Brückner, specialkonsulent, DTU 15:30-15:40 Hvordan deltager man i Horizon 2020 ved Torben Høøck Hansen, chefkonsulent, EU-kontoret, Københavns Universitet 15:40-16:00 Case 1 om erfaringer med at søge midler under FP7, Stifter Peter Thomsen, BioModics ApS Case 2 om planer for at deltage i Horizon 2020: Professor Poul Jennum, Dansk Center for Søvnmedicin, Glostrup Hospital & Københavns Universitet 16:00-16:10 Introduktion til netværkssession, matchmaking og mulighed for projektsparring ved Thomas Elmbæk Knudsen, partner, Innovayt A/S 16:10-16:15 Afrunding ved Dorthe Kjær Pedersen, Projektchef, Medico Innovation 16:15-17:30 Drinks, snacks og networking, mulighed for one-to-one møder om projektudvikling, partnersøgning og ansøgning med Thomas Elmbæk Knudsen, Innovayt A/S November 2013
Take aways Publication of first calls for proposals: o 11 December 2013 EU-DK Support o o Support Danish applications for EU programmes www.eusupport.dk November 2013
H2020 Hvad er det og hvad er nyt? Jonas Bak, EU adviser, creodk
Horizon 2020 1. Basic research Excellent science (32 %) 2. Strategic research Societal Challenges (38,5 %) 3. Innovation Industrial Leadership (22%) 4. Other activities EIT, JRC, EURATOM (7,5 %) Budget 70,2 mia. euro 525 mia. kr.
Horizon 2020 - the framework Excellent science The European Research Council (ERC) Future and Emerging Technologies (FET s) Marie Curie Actions European research infrastructures Societal Challenges (7) Health, demographic change and wellbeing Food Security, Sustainable agriculture, Marine and Maritime research and the Bio-economy Secure, clean and efficient energy Smart, green and integrated transport Climate action, ressource efficiency including raw materials Europe in a changing world - Inclusive, innovative and reflective societies Secure societies Industrial Leadership Leadership in enabling and industrial techonolgies Access to risk finance Innovation in SMEs Others JRC EIT - KIC Time to market
Horizon 2020 Proposal for a budget breakdown Inclusive soc. Secure soc. 2% 2% JRC EIT 2,5% 3,5% Climate 4% ERC 17% Medico? Transport 8% FET 3,5% Medico? Energy 8% Marie Curie 8% Bioeconomy challenges 5% Infrastructures 3% Medico? Health 10% SME 1% Risk Finance 3,5% KET 17,5% Medico?
Horizon 2020 - Timeline 1. Strategic Programme Work Programme 1 Preparing for SP Preparing for WP 2. Strategic programme Work programme 2 Preparing for SP Preparing for WP 3. Strategic programme Work programme 3 WP 4
Horizon 2020 Strategic Programme 2014-2016 What? Commissions Internal planning document laying out the main areas to be covered by funding in the H2020 sub-programmes addressing societal challenges and industrial leadership. How much? Up to 50 % of all funding from the two programmes in the first two years. What are the focus areas? Personalised health and care Sustainable food security Blue growth: Unlocking the potential of the oceans Smart cities and communities Competitive low-carbon energy Energy efficiency Mobility for growth Waste: a resource to recycle, reuse and recover raw materials Water innovation: Boosting its value for Europe Overcoming the crises: new ideas, strategies and governance structures for Europe Disaster-resilience: safeguarding and securing society, including adopting to climate change Digital security
Horizon 2020 Strategic Programme 2014-2016 The personalising health and care call aims to create opportunities for real breakthrough research and radical innovation in response to these challenges, by supporting the translation of findings into the clinic and other health and care settings to improve health outcomes, reduce health inequalities and to promote active and healthy ageing.
Horizon 2020 Need to have Excellence - European research budget cuts means that the competition will be fierce - Fewer and broader topics will generate a larger number of applicants Well developed network of International partners - Most EU projects requires participants from at least three different countries - Strong allies are priceless if you want to lobby for an idea A sense of Impact - The ability to describe and account for impact particularly in relation to the creation of growth and jobs, is a strict necessity in most topics - Improved knowledge is good but not enough The European dimension - The output of your research should be relevant/applicable to most of the EU
Horizon 2020 Nice to have SME s (Small and Medium sized Companies) - Many topics will have concrete mentioning of expected SME participation Cross-disciplinary approach - The EU recognizes that most societal challenges often can t be solved by doing research (and politics) in silo's Gender -The EU is strongly encouraging more inclusion of female researchers in research projects Widening participation -Representation from less developed member states / regions of the EU can in some cases be an advantage International Cooperation -Participation from countries outside the EU may be beneficial for an application (new markets, aid, excellent input not found elsewhere) -However most often they will have to bring their own funding
Horizon 2020 Important questions to ask yourselves Are we competetive? Beyond state of the art? Can we account for a proper impact? Is the timing right? Does it fit with the European agenda? Do we have the right partners/competences in consortia? Do we have the time to see this through? Are we clear about what we want and how we whish to achieve it?
Explore Horizon 2020 on Participants portal http://ec.europa.eu/research/participants/portal/
creodks værktøjskasse http://www.regionh.dk/creodk/menu/europaeisk_forskning/h2020_tools
Questions? creodk jonas.bak@regionh.dk www.creodk.eu
MedTech EU Topics 2014-15 Medicafe - Medico Innovation den 6. November 2013 Lars Brückner, DTU Forskning og Relationer 21
Strategic programme 2014-2016 What? Personalising health and care identified as one of the 12 focus areas to support the key drivers of the first Horizon 2020 work programmes. What are the focus areas? Personalised health and care Sustainable food security Blue growth: Unlocking the potential of the oceans Smart cities and communities Competitive low-carbon energy Energy efficiency Mobility for growth Waste: a resource to recycle, reuse and recover raw materials Water innovation: Boosting its value for Europe Overcoming the crises: new ideas, strategies and governance structures for Europe Disaster-resilience: safeguarding and securing society, including adopting to climate change Digital security 22
WP 2014-15 opportunities for medtech European Research Counsil Future and Emerging Technologies Research Infrastructures Marie Sklodowska- Curie actions 23
WP 2014-15 opportunities for medtech Leadership in enabling and industrial technologies Innovation in SMEs 24
WP 2014-15 opportunities for medtech Challenge 1 Health, demographic change and wellbeing; 25
Societal Challanges 1, 2014-15: overview WP 2014-15 = 2 calls 6 areas for call 1 Coordination activities in call 2 36 broad topics for call 1 15 topics for call 2 (3-8 topics per area)
SOCIETAL CHALLENGES 1, 2014-15 Health, demographic change and wellbeing - 1 Improving diagnosis PHC 10 2014: Development of new diagnostic tools and technologies: in vitro devices, assays and platforms PHC 11 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies Innovative treatments and technologies PHC 16 2015: Tools and technologies for advanced therapies PHC 17 2014: Comparing the effectiveness of existing healthcare interventions in the elderly PHC 18 2015: Establishing effectiveness of health care interventions in the paediatric population Advancing active and healthy ageing PHC 19 2014: Advancing active and healthy ageing with ICT: Service robotics within assisted living environments PHC 20 2014: Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment PHC 21 2015: Advancing active and healthy ageing with ICT: Early risk detection and intervention PHC 22 2015: Promoting mental wellbeing: in the ageing population 27
SOCIETAL CHALLENGES 1, 2014-15 Health, demographic change and wellbeing - 2 Integrated, sustainable, citizen-centred care PHC 23 2014: Developing and comparing new models for safe and efficient, prevention oriented, health and care systems PHC 24 2015: Piloting personalised medicine in health and care systems PHC 25 2015: Advanced ICT systems and services for Integrated Care PHC 26 2014: Self-management of health and disease: citizen engagement and mhealth PHC 27 2015: Self-management of health and disease and patient empowerment supported by ICT PHC 28 2015: Self-management of health and disease and decision support systems based on predictive computer modelling used by the patient him or herself PHC 29 2015: Public procurement of innovative ehealth services PHC 30 2015: ehealth Sectoral Inducement Prize Improving health information, data exploitation and providing an evidence base for health policies and regulation PHC 31 2015: Digital representation of health data to improve disease diagnosis and treatment PHC 32 2014: Foresight for health policy development and regulation PHC 33 2014: Advancing bioinformatics to meet biomedical and clinical needs PHC 34 2015: New approaches to improve predictive human safety testing PHC 35 2014: ehealth interoperability 28
SOCIETAL CHALLENGES 1 The topic PHC 11 2015: Development of new diagnostic tools and technologies: in vivo medical imaging technologies Specific challenge: The development of new diagnostics (more sensitive, robust and selective) for improved clinical practice demands the translation of multidisciplinary scientific and technological knowledge from diverse fields into clinical applications. Innovation in the diagnostics area relies on the development, translation and uptake of existing, new or evolving, and often complex technologies. A wide range of multidisciplinary competencies need to be brought together to develop and bring new diagnostics to the patient. This is also a field where many European companies are active. Scope: Proposals will focus on the development of innovative in vivo imaging tools and technologies (not novel applications of existing ones). Tools and technology should aim at improving diagnosis, prediction, monitoring, imagebased intervention or assessment of therapeutic response, with a significant impact on clinical decisions and health outcomes. Preference will be given to innovations that offer a clear advantage over existing tools and technologies. Development of in vivo medical imaging technologies should make use of existing high-tech engineering or physics solutions or innovative ideas and concepts coming from those fields. The Commission considers that proposals requesting a contribution from the EU between the range of EUR XXX to XXX would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Expected impact: New in vivo diagnostic tools and methods providing more accurate, more reliable and earlier disease diagnosis, prediction or response to therapy, leading to improved clinical decisions and outcomes. Contribution to the sustainability of health care systems. Growth of the European diagnostics sector, in particular for SMEs Type of action: Research and innovation action The conditions for this topic are provided in the general conditions for this call. 29
SOCIETAL CHALLENGES some basics Consortium: min. 3 European partners No budget limit From proposal to funding: 8 months One project one funding rate Maximum of 100% of the total eligible costs (except for actions close to market, where a 70% maximum will apply) Indirect eligible costs: a flat rate of 25% of direct eligible costs 30
WP 2014-15 opportunities for medtech Leadership in enabling and industrial technologies 31
Leadership in enabling and industrial technologies Emphasis on areas with strong industrial dimension Priorities informed by industrially driven research roadmaps and inputs from the European Technology Platforms The funded projects will be outcome oriented, developing key technology building blocks, bringing solutions closer to the market, and paving the way for industrial and commercial implementation, including in areas of societal challenges. 32
LEIT: Leadership in enabling and industrial technologies, 2014-15 LEIT Nanotechnologies, Advanced Materials and KET support actions Scale-up of nanomedicine production Networking of SMEs in the nano-biomedical sector Nanomedicine therapy for cancer Biomaterials for treatment and prevention of Alzheimer s disease LEIT Biotechnologies Cutting-edge biotechnologies as future innovation drivers Synthetic biology design of organisms for new products and processes New bioinformatics approaches in service of biotechnology Innovative and competitive platform technologies Metagenomics as innovation driver LEIT ICT Smart cyber-physical systems Smart system integration Advanced thin, organic and large area electronics technologies Multimodal and natural computer interaction Micro- and nano-electronic technologies, Photonics Generic Technology Development on micro- and nano-electronics Photonics KET 33
WP2014-15: time line October December 2013: Finalising the first Work Programme draft work programmes circulate unofficially 11 December 2013: Launch of calls for 2014 expected. All information including the Work Programmes and deadlines will be available on the Horizon 2020 Participant Portal. 27 February 2014: European Commission information day in Brussels on challenge 2 and LEIT Biotechnology. Primo April 2014 Mid-end 2014: Deadlines for proposals 2014 calls (indicative). Ultimo 2014 Mid 2015: Deadlines for proposals 2014 calls (indicative). 34
Questions? Labru@adm.dtu.dk 35
Forskning & Innovation Hvorfor deltage i Horizon 2020? Torben Høøck Hansen Forskning & Innovation EU Kontoret DTU, 6. november 2013 Dias 36
Disclaimer What you are about to hear is mainly related to big collaborative multi-partner projects My views are based on experience from FP3 - FP7 Horizon 2020 have a lot of new features, not all are yet disclosed in detail so we all have to be alert
Yes, there are rules, but. As potential applicants, at this stage you only need to know: You must to have at least two partners Must not be from the same member state Must be independent from each other Must be a legal entity That your project is within the scope of the topic you apply under in short: you can deliver what EU wants
The really bad reasons for participating Money - in the sense you want to generate a profit you can spend on other projects / new or unforseen research & innovation activities within the project Urgent need of funds for a (on-going?) project
The very good reason for being part of a EU project It will be a project you are unable to do on your own* and will most likely have far more impact than most things your own group could do alone (*if you could, EU would never fund it)
Other positive drivers in a collaborative project You get a new network, or improve existing ones You get access to a pool of knowledge you could not develop on your own You are in a good position to influence EU on future work programmes and other initiatives Being part of a successful EU project will be noticed by those going to fund your next project
Network and knowledge In Horizon 2020 a lot of projects will be crossdisciplinary shortcut into fields outside your own Cross-sectoral too access to industry, research organisations, public providers, regulatory bodies, patient organisations etc. Access to a lot of brainpower, cohorts, databases, biobanks etc. New perspectives your partners might have insights and ideas that point you in new directions
Influence and spin-off EU pay more attention to results they have paid for (in case you want to lobby for something in the future) Use the EU project as leverage for applying for e.g. Marie Curie fellowships (swap good researchers with your partners, EU pick up the bill) Most national research councils and private foundations see it as a mark of quality that the applicant have been leader of (or part of) a big successful project
A successful consortium depends on the topic An example where one perhaps would have to look outside ones normal range of collaborators: PHC 4 2015: Health promotion and disease prevention: improved inter-sector cooperation for environment and health based interventions Specific challenge: Better health promotion and disease prevention interventions can make a significant contribution to equitable.[] health in all policies approach has been identified as a promising means [] requires a multi-sector approach that aims to improve health by addressing such factors as housing; water and sanitation systems; transportation; communication, education and information; occupational health and safety; food production and distribution, and the physical and social environments. Scope: Given the breadth of sectors, the specific focus of this topic for 2015 is the integration of environment and health sectors (including but not limited to climate change, air quality, water and sanitation, workplace, etc.). Using a multidisciplinary approach and involving relevant stakeholders such as policy makers, the private sector, civil society organisations etc. proposals will: Develop inter-sector interventions (and/or policy initiatives) to promote health or prevent disease based on existing evidence. These interventions will address key environmental stressors for which changes in relevant EU and international policies related to environment and health would have the greatest impact; Document success characteristics of these interventions, including those which overcome barriers to inter-sector co-operation; contextual factors such as the interplay between politics and economics should be addressed;